This chapter explores Compass Pathways, a company focused on using magic mushrooms for suicide treatment. They discuss the company's plans for reporting phase three data and the optimism for FDA approval in 2025. The speakers also touch on the history of psychedelics, the efficacy and safety of their use, and the potential approval of MDMA for PTSD.
The Sunday Times' tech correspondent Danny Fortson brings on Christian Angermayer, founder of Apeiron Investments, to talk about psychedelics in Oregon (4:15), the spiritual experience of a “trip” (11:30), progressing toward the first FDA approval (15:30), how this will be introduced into the market (21:10), why having a qualified guide/therapist is critical (25:30), gaining societal acceptance (30:20), why he funded the longevity XPrize (34:20), the new approach to ageing (41:00), why we are on the cusp of a breakthrough in life span (42:30), the Ozempic effect (49:00, thriving in a toxic society (56:20), and how AI dovetails with psychedelics and longevity (1:01:50).
Hosted on Acast. See acast.com/privacy for more information.